Population Pharmacokinetic/pharmacodynamic Modelling of Nifekalant in Healthy Chinese Volunteers

Jiashan Zhang,Ying Zan,Hua Huo,Yanfang Liu,Yunbiao Tang,Yaling Han
DOI: https://doi.org/10.1016/j.ejps.2020.105385
IF: 5.112
2020-01-01
European Journal of Pharmaceutical Sciences
Abstract:Nifekalant is a class III antiarrhythmic drug, and its major adverse effect is prolongation of the QT interval. This study analysed data generated from a pharmacokinetic (PK) study to develop a population PK/pharmacody- namics (PD) model for describing the relationship between plasma concentrations and prolongation of the QT interval over time following intravenous administration of nifekalant. This open -labelled, phase I clinical study comprised two dose level groups of eight healthy Chinese volunteers. Concentrations of nifekalant in plasma samples collected at set time -points were determined using a liquid chromatography -tandem mass spectrometry (LC-MS/MS) method. A PK/PD model was constructed using a non-linear mixed -effects approach (Phoenix NLME 8.1). Furthermore, demographic covariates of the model were investigated and a concentration factor (Conc ? ) was introduced as the only covariate which improved the performance of the model. The final popu- lation PK model exhibited one -order elimination with two -compartment distribution and adequately described nifekalant plasma concentrations over time. The QT interval prolongation was best described by an indirect effect model with an inhibition build-up effect, representing the relationship between plasma concentrations and effect. The final population PK/PD model may facilitate more accurate predictions of the drug profile in clinical settings in the future.
What problem does this paper attempt to address?